After taking a market share lead in the crowded Humira biosimilar space and with other key launches in the works, Novartis spinout Sandoz is raising its full-year sales guidance. Sandoz previously ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

(Reuters) - AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the ...

(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

Please provide your email address to receive an email when new articles are posted on . CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national ...

CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira. It will be priced more than 80% lower than the current list price of ...

The biggest U.S. drug benefits manager is making a move that will take a bite out of sales for the world’s top-selling medication. CVS Health Corp. will remove AbbVie’s Humira from most of its lists ...

In May 2025, the FDA approved numerous biosimilars as interchangeable with Stelara ® (ustekinumab) and Humira ® (adalimumab), bringing the total number of Stelara ® interchangeables to four, plus an ...

(Reuters) -Germany's Boehringer Ingelheim on Monday launched an unbranded version of its biosimilar of AbbVie's Humira with a list price 81% cheaper than the blockbuster rheumatoid arthritis drug. The ...